At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 339 enrolled
Drug / intervention
Duloxetine hydrochloride +1 moredrug
Likely dose
Duloxetine hydrochloride 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Eight-Week, Randomized, Double Blind, Two Parallel Groups, Study to Assess Clinical Response of Duloxetine 60 mg and 120 Per Day in Patients Hospitalized for Severe Depression
In Brief
A Phase 4 clinical trial evaluating Duloxetine hydrochloride and Placebo for Major Depressive Disorder. Completed, enrolled 339 participants across 35 sites in 4 countries.
Detailed Summary
An eight-week, randomized, double blind, two parallel groups, study to assess clinical response of duloxetine 60 milligrams (mg) and 120 mg per day in patients hospitalized for severe depression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesFrance, Italy, Russia, South Africa
CollaboratorsBoehringer Ingelheim
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2007
Enrollment StartFeb 2007
Primary CompletionAug 2008
TodayJul 2026
First PostedJan 15, 2007
Enrollment StartFeb 1, 2007
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 19.5 years ago
Interventions
Duloxetine hydrochloridedrug
60 mg once or twice a day, by mouth
Placebodrug
placebo capsule by mouth